Burks A Wesley, Harthoorn Lucien F, Van Ampting Marleen T J, Oude Nijhuis Manon M, Langford Jane E, Wopereis Harm, Goldberg Steven B, Ong Peck Y, Essink Brandon J, Scott Robert B, Harvey Bryan M
University of North Carolina, Chapel Hill, NC, USA.
Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
Pediatr Allergy Immunol. 2015 Jun;26(4):316-22. doi: 10.1111/pai.12390.
Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires diets that are not only hypoallergenic but also support adequate growth in this population. This study assessed growth of CMA infants when using a new amino acid-based formula (AAF) with prebiotics and probiotics (synbiotics) and evaluated its safety in the intended population.
In a prospective, randomized, double-blind controlled study, full-term infants with diagnosed CMA received either an AAF (control; n = 56) or AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V) (test; n = 54) for 16 wk. Primary outcome was growth, measured as weight, length and head circumference. Secondary outcomes included allergic symptoms and stool characteristics.
Average age (±SD) of infants at inclusion was 4.5 ± 2.4 months. Both formulas equally supported growth according to WHO 2006 growth charts and resulted in similar increases of weight, length and head circumference. At week 16, differences (90% CI) in Z-scores (test-control) were as follows: weight 0.147 (-0.10; 0.39, p = 0.32), length -0.299 (-0.69; 0.09, p = 0.21) and head circumference 0.152 (-0.15; 0.45, p = 0.40). Weight-for-age and length-for-age Z-scores were not significantly different between the test and control groups. Both formulas were well tolerated and reduced allergic symptoms; the number of adverse events was not different between the groups.
This is the first study that shows that an AAF with a specific synbiotic blend, suitable for CMA infants, supports normal growth and growth similar to the AAF without synbiotics. This clinical trial is registered as NCT00664768.
牛奶过敏(CMA)儿童存在营养摄入不足和生长发育受影响的风险。因此,CMA的饮食管理需要采用不仅低敏而且能支持该人群充分生长发育的饮食。本研究评估了使用含益生元和益生菌(合生元)的新型氨基酸基配方奶粉(AAF)时CMA婴儿的生长情况,并评估了其在目标人群中的安全性。
在一项前瞻性、随机、双盲对照研究中,确诊为CMA的足月婴儿接受AAF(对照组;n = 56)或含合生元(低聚果糖、长链菊粉、酸性寡糖、短双歧杆菌M - 16V)的AAF(试验组;n = 54),为期16周。主要结局指标为生长情况,通过体重、身长和头围来衡量。次要结局指标包括过敏症状和粪便特征。
纳入研究的婴儿平均年龄(±标准差)为4.5 ± 2.4个月。根据世界卫生组织2006年生长图表,两种配方奶粉均同样支持生长,体重、身长和头围的增长相似。在第16周时,Z评分(试验组 - 对照组)的差异(90%置信区间)如下:体重0.147(-0.10;0.39,p = 0.32),身长 -0.299(-0.69;0.09,p = 0.21),头围0.152(-0.15;0.45,p = 0.40)。试验组和对照组之间的年龄别体重和年龄别身长Z评分无显著差异。两种配方奶粉耐受性均良好,且能减轻过敏症状;两组间不良事件数量无差异。
这是第一项表明含特定合生元组合的AAF适用于CMA婴儿,能支持正常生长且生长情况与不含合生元的AAF相似的研究。本临床试验已注册,注册号为NCT00664768。